FDA clears MSD’s Keytruda combo plus Welireg for ccRCC treatment

IPF is a chronic, progressive lung disease with no known cause, marked by the development of fibrosis in the lung interstitium. Credit: SkazovD / Shutterstock.com.



  • FDA MSD Keytruda Welireg